{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:30:50Z","timestamp":1789421450095,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00277-014-2224-8","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T05:00:56Z","timestamp":1413176456000},"page":"1953-1963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (\u00d6GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)"],"prefix":"10.1007","volume":"93","author":[{"given":"Stephan","family":"Kreher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf U.","family":"Trappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petro E.","family":"Petrides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Matzdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"2224_CR1","volume-title":"WHO classification of tumours of haemopoietic and lymphoid tissues","author":"SHCE Swerdlow","year":"2008","unstructured":"Swerdlow SHCE, Harris NL et al (2008) WHO classification of tumours of haemopoietic and lymphoid tissues. IARC Press, Lyon, France"},{"issue":"1","key":"2224_CR2","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34(1):29\u201339","journal-title":"Semin Hematol"},{"issue":"3","key":"2224_CR3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","volume":"32","author":"P Johansson","year":"2006","unstructured":"Johansson P (2006) Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32(3):171\u2013173. doi: 10.1055\/s-2006-939430","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2224_CR4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","volume":"65","author":"MK Jensen","year":"2000","unstructured":"Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC (2000) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 65(2):132\u2013139","journal-title":"Eur J Haematol"},{"key":"2224_CR5","author":"J Mehta","year":"2013","unstructured":"Mehta J, Wang H, Iqbal SU, Mesa R (2013) Epidemiology of myeloproliferative neoplasms (MPN) in the United States. Leuk Lymphoma. doi: 10.3109\/10428194.2013.813500","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2224_CR6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342(17):1255\u20131265. doi: 10.1056\/NEJM200004273421706","journal-title":"N Engl J Med"},{"issue":"25","key":"2224_CR7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390. doi: 10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"issue":"6","key":"2224_CR8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770. doi: 10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"issue":"9","key":"2224_CR9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12(9):599\u2013612. doi: 10.1038\/nrc3343","journal-title":"Nat Rev Cancer"},{"issue":"9464","key":"2224_CR10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054\u20131061. doi: 10.1016\/S0140-6736(05)71142-9","journal-title":"Lancet"},{"issue":"7037","key":"2224_CR11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144\u20131148. doi: 10.1038\/nature03546","journal-title":"Nature"},{"issue":"4","key":"2224_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397. doi: 10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"issue":"10","key":"2224_CR13","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108(10):3472\u20133476. doi: 10.1182\/blood-2006-04-018879","journal-title":"Blood"},{"issue":"3","key":"2224_CR14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F, Villani L, Finotto S, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A, Barbui T (2008) Characteristics and clinical correlates of MPL 515W\u2009>\u2009L\/K mutation in essential thrombocythemia. Blood 112(3):844\u2013847. doi: 10.1182\/blood-2008-01-135897","journal-title":"Blood"},{"issue":"9501","key":"2224_CR15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945\u20131953. doi: 10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"},{"issue":"25","key":"2224_CR16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405. doi: 10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"issue":"10","key":"2224_CR17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232. doi: 10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"issue":"11","key":"2224_CR18","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","volume":"22","author":"R Landolfi","year":"2008","unstructured":"Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22(11):2020\u20132028. doi: 10.1038\/leu.2008.253","journal-title":"Leukemia"},{"issue":"4","key":"2224_CR19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/leu.2011.314","volume":"26","author":"H Reikvam","year":"2012","unstructured":"Reikvam H, Tiu RV (2012) Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 26(4):563\u2013571. doi: 10.1038\/leu.2011.314","journal-title":"Leukemia"},{"issue":"6","key":"2224_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2010.08.002","volume":"24","author":"E Papadakis","year":"2010","unstructured":"Papadakis E, Hoffman R, Brenner B (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 24(6):227\u2013232. doi: 10.1016\/j.blre.2010.08.002","journal-title":"Blood Rev"},{"issue":"2","key":"2224_CR21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","volume":"130","author":"MF McMullin","year":"2005","unstructured":"McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, Oscier D, Polkey MI, Reilly JT, Rosenthal E, Ryan K, Pearson TC, Wilkins B (2005) Guidelines for the diagnosis, investigation and management of polycythaemia\/erythrocytosis. Br J Haematol 130(2):174\u2013195. doi: 10.1111\/j.1365-2141.2005.05535.x","journal-title":"Br J Haematol"},{"issue":"3","key":"2224_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275\u2013290. doi: 10.1111\/j.1365-2141.2004.05277.x","journal-title":"Br J Haematol"},{"issue":"2","key":"2224_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","volume":"81","author":"AP Wolanskyj","year":"2006","unstructured":"Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81(2):159\u2013166. doi: 10.4065\/81.2.159","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2224_CR24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.23135","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A (2012) Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(3):285\u2013293. doi: 10.1002\/ajh.23135","journal-title":"Am J Hematol"},{"issue":"1","key":"2224_CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33\u201345. doi: 10.1056\/NEJMoa043800","journal-title":"N Engl J Med"},{"key":"2224_CR26","author":"A Casini","year":"2013","unstructured":"Casini A, Fontana P, Lecompte T (2013) Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. doi: 10.1111\/jth.12265","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2224_CR27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G, Barosi G (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778\u2013782. doi: 10.1182\/blood-2009-08-238956","journal-title":"Blood"},{"issue":"4","key":"2224_CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33(4):313\u2013320. doi: 10.1055\/s-2007-976165","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2224_CR29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372\u2013380. doi: 10.3324\/haematol.12053","journal-title":"Haematologica"},{"key":"2224_CR30","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. doi: 10.1038\/leu.2013.163","journal-title":"Leukemia"},{"issue":"10","key":"2224_CR31","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"111","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922\u20134929. doi: 10.1182\/blood-2007-11-125328","journal-title":"Blood"},{"issue":"9","key":"2224_CR32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/MPH.0b013e3181b1ec9e","volume":"31","author":"H Kurosawa","year":"2009","unstructured":"Kurosawa H, Okuya M, Matsushita T, Kubota T, Endoh K, Kuwashima S, Hagisawa S, Sato Y, Fukushima K, Sugita K, Okada Y, Park MJ, Hayashi Y, Arisaka O (2009) JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. J Pediatr Hematol Oncol 31(9):678\u2013680. doi: 10.1097\/MPH.0b013e3181b1ec9e","journal-title":"J Pediatr Hematol Oncol"},{"issue":"16","key":"2224_CR33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF01725198","volume":"67","author":"BR Anger","year":"1989","unstructured":"Anger BR, Seifried E, Scheppach J, Heimpel H (1989) Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 67(16):818\u2013825","journal-title":"Klin Wochenschr"},{"issue":"7","key":"2224_CR34","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","volume":"130","author":"RK Patel","year":"2006","unstructured":"Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gaken J, Wendon J, Heaton ND, Mufti GJ (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130(7):2031\u20132038. doi: 10.1053\/j.gastro.2006.04.008","journal-title":"Gastroenterology"},{"issue":"4","key":"2224_CR35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","volume":"5","author":"S Regina","year":"2007","unstructured":"Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5(4):859\u2013861. doi: 10.1111\/j.1538-7836.2007.02384.x","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2224_CR36","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2006-05-021527","volume":"108","author":"M Boissinot","year":"2006","unstructured":"Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C, Praloran V, Hermouet S (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 108(9):3223\u20133224. doi: 10.1182\/blood-2006-05-021527","journal-title":"Blood"},{"issue":"1","key":"2224_CR37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","volume":"5","author":"D Colaizzo","year":"2007","unstructured":"Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5(1):55\u201361. doi: 10.1111\/j.1538-7836.2006.02277.x","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2224_CR38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","volume":"129","author":"Y Chait","year":"2005","unstructured":"Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Briere JB (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129(4):553\u2013560. doi: 10.1111\/j.1365-2141.2005.05490.x","journal-title":"Br J Haematol"},{"issue":"3","key":"2224_CR39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-2006-939432","volume":"32","author":"JB Briere","year":"2006","unstructured":"Briere JB (2006) Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 32(3):208\u2013218. doi: 10.1055\/s-2006-939432","journal-title":"Semin Thromb Hemost"},{"issue":"25","key":"2224_CR40","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921\u20134928. doi: 10.1182\/blood-2011-09-376517","journal-title":"Blood"},{"issue":"6","key":"2224_CR41","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","volume":"44","author":"M Primignani","year":"2006","unstructured":"Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44(6):1528\u20131534. doi: 10.1002\/hep.21435","journal-title":"Hepatology"},{"key":"2224_CR42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","volume":"2012","author":"A Falanga","year":"2012","unstructured":"Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Prog 2012:571\u2013581. doi: 10.1182\/asheducation-2012.1.571","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"1","key":"2224_CR43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","volume":"110","author":"MK Jensen","year":"2000","unstructured":"Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 110(1):116\u2013124","journal-title":"Br J Haematol"},{"issue":"13","key":"2224_CR44","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96(13):4261\u20134266","journal-title":"Blood"},{"issue":"4","key":"2224_CR45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","volume":"42","author":"A Falanga","year":"2005","unstructured":"Falanga A, Marchetti M, Barbui T, Smith CW (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 42(4):239\u2013247. doi: 10.1053\/j.seminhematol.2005.05.023","journal-title":"Semin Hematol"},{"issue":"5","key":"2224_CR46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","volume":"33","author":"A Falanga","year":"2005","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T (2005) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 33(5):523\u2013530. doi: 10.1016\/j.exphem.2005.01.015","journal-title":"Exp Hematol"},{"issue":"4","key":"2224_CR47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","volume":"114","author":"T Barbui","year":"2009","unstructured":"Barbui T, Carobbio A, Rambaldi A, Finazzi G (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114(4):759\u2013763. doi: 10.1182\/blood-2009-02-206797","journal-title":"Blood"},{"issue":"10","key":"2224_CR48","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","volume":"112","author":"M Marchetti","year":"2008","unstructured":"Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112(10):4061\u20134068. doi: 10.1182\/blood-2008-06-164087","journal-title":"Blood"},{"issue":"3","key":"2224_CR49","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","volume":"110","author":"MP Wautier","year":"2007","unstructured":"Wautier MP, El Nemer W, Gane P, Rain JD, Cartron JP, Colin Y, Le Van Kim C, Wautier JL (2007) Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM. Blood 110(3):894\u2013901. doi: 10.1182\/blood-2006-10-048298","journal-title":"Blood"},{"issue":"3","key":"2224_CR50","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.hoc.2010.03.004","volume":"24","author":"BD Adams","year":"2010","unstructured":"Adams BD, Baker R, Lopez JA, Spencer S (2010) Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am 24(3):585\u2013602. doi: 10.1016\/j.hoc.2010.03.004","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2224_CR51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","volume":"121","author":"V Rosti","year":"2013","unstructured":"Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L, Bergamaschi G, Catarsi P, Dallera E, Novara F, Massa M, Campanelli R, Fois G, Peruzzi B, Lucioni M, Guglielmelli P, Pancrazzi A, Fiandrino G, Zuffardi O, Magrini U, Paulli M, Vannucchi AM, Barosi G (2013) Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 121(2):360\u2013368. doi: 10.1182\/blood-2012-01-404889","journal-title":"Blood"},{"issue":"3","key":"2224_CR52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2010.06.025","volume":"126","author":"J Duchemin","year":"2010","unstructured":"Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF (2010) Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126(3):238\u2013242. doi: 10.1016\/j.thromres.2010.06.025","journal-title":"Thromb Res"},{"issue":"1","key":"2224_CR53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9","volume":"52","author":"A Bucalossi","year":"1996","unstructured":"Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E (1996) Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 52(1):14\u201320. doi: 10.1002\/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9","journal-title":"Am J Hematol"},{"issue":"5","key":"2224_CR54","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","volume":"35","author":"A Falanga","year":"2007","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35(5):702\u2013711","journal-title":"Exp Hematol"},{"issue":"1","key":"2224_CR55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH09-09-0663","volume":"104","author":"G Cella","year":"2010","unstructured":"Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A (2010) Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 104(1):151\u2013156. doi: 10.1160\/TH09-09-0663","journal-title":"Thromb Haemost"},{"issue":"3","key":"2224_CR56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1532\/IJH97.E0316","volume":"79","author":"M Karakantza","year":"2004","unstructured":"Karakantza M, Giannakoulas NC, Zikos P, Sakellaropoulos G, Kouraklis A, Aktypi A, Metallinos IC, Theodori E, Zoumbos NC, Maniatis A (2004) Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 79(3):253\u2013259","journal-title":"Int J Hematol"},{"issue":"2","key":"2224_CR57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96(2):315\u2013318. doi: 10.3324\/haematol.2010.031070","journal-title":"Haematologica"},{"issue":"2","key":"2224_CR58","first-page":"345","volume":"84","author":"AB Federici","year":"2000","unstructured":"Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84(2):345\u2013349","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"2224_CR59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10428199609074364","volume":"22","author":"PJ Genderen van","year":"1996","unstructured":"van Genderen PJ, Leenknegt H, Michiels JJ, Budde U (1996) Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 22(Suppl 1):79\u201382. doi: 10.3109\/10428199609074364","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2224_CR60","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Gangat N, Wolanskyj AP (2006) Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 108(7):2493\u20132494. doi: 10.1182\/blood-2006-05-025544","journal-title":"Blood"},{"issue":"6","key":"2224_CR61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","volume":"32","author":"JJ Michiels","year":"2006","unstructured":"Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH (2006) The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 32(6):589\u2013604. doi: 10.1055\/s-2006-949664","journal-title":"Semin Thromb Hemost"},{"key":"2224_CR62","doi-asserted-by":"crossref","first-page":"794240","DOI":"10.1155\/2011\/794240","volume":"2011","author":"R Marchioli","year":"2011","unstructured":"Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T (2011) The CYTO-PV: a large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thromb 2011:794240. doi: 10.1155\/2011\/794240","journal-title":"Thromb"},{"issue":"3","key":"2224_CR63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hon.816","volume":"25","author":"F Radaelli","year":"2007","unstructured":"Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A (2007) Analysis of risk factors predicting thrombotic and\/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol 25(3):115\u2013120. doi: 10.1002\/hon.816","journal-title":"Hematol Oncol"},{"issue":"2","key":"2224_CR64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","volume":"13","author":"C Besses","year":"1999","unstructured":"Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13(2):150\u2013154","journal-title":"Leukemia"},{"issue":"6","key":"2224_CR65","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6):2310\u20132313. doi: 10.1182\/blood-2006-09-046342","journal-title":"Blood"},{"issue":"6","key":"2224_CR66","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446\u20132452. doi: 10.1182\/blood-2006-08-042515","journal-title":"Blood"},{"issue":"5","key":"2224_CR67","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2011.08903.x","volume":"156","author":"F Palandri","year":"2012","unstructured":"Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N (2012) Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years. Br J Haematol 156(5):676\u2013679. doi: 10.1111\/j.1365-2141.2011.08903.x","journal-title":"Br J Haematol"},{"issue":"1","key":"2224_CR68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333. doi: 10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"issue":"3","key":"2224_CR69","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical profile of homozygous JAK2 617V\u2009>\u2009F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840\u2013846. doi: 10.1182\/blood-2006-12-064287","journal-title":"Blood"},{"issue":"1","key":"2224_CR70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","volume":"33","author":"IJ Dahabreh","year":"2009","unstructured":"Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33(1):67\u201373. doi: 10.1016\/j.leukres.2008.06.006","journal-title":"Leuk Res"},{"issue":"9","key":"2224_CR71","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952\u20131959. doi: 10.1038\/sj.leu.2404854","journal-title":"Leukemia"},{"issue":"9","key":"2224_CR72","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","volume":"37","author":"A Carobbio","year":"2009","unstructured":"Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37(9):1016\u20131021. doi: 10.1016\/j.exphem.2009.06.006","journal-title":"Exp Hematol"},{"issue":"3","key":"2224_CR73","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106(3):631\u2013635. doi: 10.1002\/cncr.21645","journal-title":"Cancer"},{"issue":"3","key":"2224_CR74","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138(3):354\u2013358. doi: 10.1111\/j.1365-2141.2007.06674.x","journal-title":"Br J Haematol"},{"key":"2224_CR75","author":"E Rumi","year":"2013","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M (2013) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. doi: 10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"key":"2224_CR76","author":"G Rotunno","year":"2013","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi A (2013) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. doi: 10.1182\/blood-2013-11-538983","journal-title":"Blood"},{"issue":"22","key":"2224_CR77","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857\u20135859. doi: 10.1182\/blood-2011-02-339002","journal-title":"Blood"},{"issue":"1","key":"2224_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10153","volume":"71","author":"M Ruggeri","year":"2002","unstructured":"Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 71(1):1\u20136. doi: 10.1002\/ajh.10153","journal-title":"Am J Hematol"},{"issue":"6","key":"2224_CR79","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/CCO.0b013e32834bb867","volume":"23","author":"T Barbui","year":"2011","unstructured":"Barbui T (2011) How to manage thrombosis in myeloproliferative neoplasms. Curr Opin Oncol 23(6):654\u2013658. doi: 10.1097\/CCO.0b013e32834bb867","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"2224_CR80","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3324\/haematol.12604","volume":"93","author":"R Landolfi","year":"2008","unstructured":"Landolfi R, Di Gennaro L (2008) Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 93(3):331\u2013335. doi: 10.3324\/haematol.12604","journal-title":"Haematologica"},{"key":"2224_CR81","doi-asserted-by":"crossref","unstructured":"(1981) Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. \u201cLeukemia and Hematosarcoma\u201d Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 44 (1):75\u201380","DOI":"10.1038\/bjc.1981.150"},{"issue":"2","key":"2224_CR82","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114\u2013124. doi: 10.1056\/NEJMoa035572","journal-title":"N Engl J Med"},{"issue":"8","key":"2224_CR83","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A Alvarez-Larran","year":"2010","unstructured":"Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, Ayats R, Salvador C, Muntanola A, Bellosillo B, Vicente V, Hernandez-Nieto L, Burgaleta C, Xicoy B, Besses C (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116(8):1205\u20131210. doi: 10.1182\/blood-2010-01-263319 , quiz 1387","journal-title":"Blood"},{"issue":"17","key":"2224_CR84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132\u20131136. doi: 10.1056\/NEJM199504273321704","journal-title":"N Engl J Med"},{"key":"2224_CR85","author":"A Alvarez-Larran","year":"2013","unstructured":"Alvarez-Larran A, Pereira A, Arellano-Rodrigo E, Hernandez-Boluda JC, Cervantes F, Besses C (2013) Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol. doi: 10.1111\/bjh.12321","journal-title":"Br J Haematol"},{"issue":"10","key":"2224_CR86","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 121(10):1720\u20131728. doi: 10.1182\/blood-2012-07-443770","journal-title":"Blood"},{"key":"2224_CR87","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kiladjian J, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison C, Pane F, Zachee P, Mesa R, He S, Jones M, Garrett W, Li J, Pirron U, Lawniczek T, Vannucchi A (2014) J Clin Oncol 32:5s, (suppl; abstr 7026)","DOI":"10.1200\/jco.2014.32.15_suppl.7026"},{"issue":"3","key":"2224_CR88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.2005.05400.x","volume":"129","author":"C Harrison","year":"2005","unstructured":"Harrison C (2005) Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 129(3):293\u2013306. doi: 10.1111\/j.1365-2141.2005.05400.x","journal-title":"Br J Haematol"},{"issue":"2","key":"2224_CR89","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","volume":"111","author":"M Ruggeri","year":"2008","unstructured":"Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Mico C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111(2):666\u2013671. doi: 10.1182\/blood-2007-07-102665","journal-title":"Blood"},{"issue":"2","key":"2224_CR90","first-page":"215","volume":"89","author":"T Barbui","year":"2004","unstructured":"Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89(2):215\u2013232","journal-title":"Haematologica"},{"issue":"2 Suppl","key":"2224_CR91","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","volume":"141","author":"GH Guyatt","year":"2012","unstructured":"Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):7S\u201347S. doi: 10.1378\/chest.1412S3","journal-title":"Chest"},{"key":"2224_CR92","unstructured":"Interdisziplin\u00e4re S2-Leitlinie: Diagnostik und Therapie der Venenthrombose und der Lungenembolie (2010) Eur J Vasc Med 39\u2009\u00b7\u2009S\/78"},{"issue":"5","key":"2224_CR93","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.21128","volume":"83","author":"G Spectre","year":"2008","unstructured":"Spectre G, Kalish Y, Schliamser L, Varon D (2008) Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol 83(5):420\u2013423. doi: 10.1002\/ajh.21128","journal-title":"Am J Hematol"},{"issue":"3","key":"2224_CR94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000280466","volume":"123","author":"ML Randi","year":"2010","unstructured":"Randi ML, Tezza F, Scapin M, Duner E, Scarparo P, Scandellari R, Fabris F (2010) Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol 123(3):140\u2013145. doi: 10.1159\/000280466","journal-title":"Acta Haematol"},{"key":"2224_CR95","volume":"1","author":"JF Heijden van der","year":"2002","unstructured":"van der Heijden JF, Hutten BA, Buller HR, Prins MH (2002) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 1, CD002001. doi: 10.1002\/14651858.CD002001","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2224_CR96","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062\u20131072. doi: 10.1016\/j.amjmed.2006.02.022","journal-title":"Am J Med"},{"issue":"2","key":"2224_CR97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153. doi: 10.1056\/NEJMoa025313","journal-title":"N Engl J Med"},{"key":"2224_CR98","volume":"10","author":"A Andras","year":"2012","unstructured":"Andras A, Sala Tenna A, Crawford F (2012) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 10, CD002001. doi: 10.1002\/14651858.CD002001.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"6 Suppl","key":"2224_CR99","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):257S\u2013298S. doi: 10.1378\/chest.08-0674","journal-title":"Chest"},{"issue":"11","key":"2224_CR100","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","volume":"9","author":"J Hoekstra","year":"2011","unstructured":"Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL (2011) Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost 9(11):2208\u20132214. doi: 10.1111\/j.1538-7836.2011.04484.x","journal-title":"J Thromb Haemost"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2224-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2224-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T18:48:32Z","timestamp":1598381312000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2224-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2224"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2224-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}